

技術分析



分析師

大中華區研究團隊

research-hk@uobkh.com

譚文漢，特許財務分析師

munhon.tham@uobkh.com

+852 2236 6799

聯想集團 (0992 HK)

最後價格:	港幣 23.16 元
支撐位:	港幣 19.42 元/港幣 15.70 元
阻力位:	港幣 26.78 元/港幣 28.28 元

技術分析:

价格行为跌破其前期支撑区域，彻底作废了此前的需求地基，并确认了更广泛主导标记下行序列的结构性延续。尽管 RSI 指标正在临近超卖参数区域，但其持续的看跌排列与向下轨迹反映出强烈的卖方速度，而非即时的结构性反转或看涨背离。只要价格行为在随后的暂态向上回踩中严格受制于这一新转换的阻力屏障下方，最小阻力路径将高度倾斜于向下方更深的主导需求目标展开持续的下行拓展。

平均時限：約兩週。

藥明生物 (2269 HK)

最後價格:	港幣 45.26 元
支撐位:	港幣 39.44 元/港幣 36.96 元
阻力位:	港幣 51.55 元/港幣 52.65 元

技術分析:

价格行为贯穿其前期支撑基线，彻底作废了既有的需求地基。RSI 指标稳固扎根于看跌区间，并持续以负向速度呈向上斜率向下倾斜，信号呈现卖方动能的持续扩张而非即时的结构性衰竭或背离。只要价格行为在随后的暂态向上回踩中严格受制于这一新转换的阻力天花板下方，最小阻力路径将高度倾斜于向下方更深的主导需求目标展开持续的下行拓展。

平均時限：約兩週。

IMPORTANT NOTICE - DISCLOSURES AND DISCLAIMERS

This report is provided subject to various disclosures and disclaimers (the "Disclosures / Disclaimers") which form an integral part of this report and are available at [this link](#) or by scanning the QR code below:



The Disclosures / Disclaimers contain important information, including without limitation, (a) exclusions of liability, (b) confidentiality obligations, (c) restrictions on publication, circulation, reproduction, distribution and use of the report, (d) potential conflicts of interest, and (e) disclosures and requirements specific to recipients in the United States and other applicable jurisdictions.

Specifically, this report is intended for general circulation and informational purposes only and does not take into account the specific investment objectives, financial situation, or particular needs of any individual person. It is not intended to constitute personal investment advice or a recommendation to buy or sell any investment product or security. You should independently evaluate the information and, where necessary, seek advice from a qualified financial adviser regarding the suitability of any investment, taking into account your specific objectives, financial situation and needs, before making any investment decision. Analyst certifications required under applicable regulations, including SEC Regulation AC (where relevant), are included in this report.

Recipients of this report must carefully read, review and understand the full Disclosures / Disclaimers before using or relying on any information in this report. By accessing, receiving or using this report, you acknowledge and confirm that you have read, understood, accepted and agreed to be bound by the Disclosures / Disclaimers (as may be amended or updated from time to time) in full."